Effects of Canagliflozin (CANA) on Biomarkers of Cardiovascular (CV) Stress in Older Patients with Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Januzzi, James L.
Butler, Javed
Jarolim, Petr
Sattar, Naveed
Vijapurkar, Ujjwala
Merton, Katherine W.
Ren, Jimmy
Canovatchel, William
Desai, Mehul
Davies, Michael J.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
150-LB
引用
收藏
页码：LB40 / LB40
页数：1
相关论文
共 50 条
  • [1] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Pfeifer, Michael
    Townsend, Raymond
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Ren, Jimmy
    [J]. DIABETES, 2016, 65 : A303 - A303
  • [2] Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)
    Gavin, James R., III
    Davies, Melanie J.
    Davies, Michael
    Vija-Purkar, Ujjwala
    Alba, Maria
    [J]. DIABETES, 2014, 63 : A285 - A285
  • [3] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nyirjesy, Paul
    Sobel, Jack
    Fung, Albert
    Gassmann-Mayer, Cristiana
    Ways, Kirk
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A276 - A276
  • [4] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Blonde, Lawrence
    Woo, Vincent
    Mathieu, Chantal
    Yee, Jacqueline
    Vijapurkar, Ujjwala
    Meininger, Gary
    [J]. DIABETES, 2014, 63 : A284 - A284
  • [5] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
    Tamborlane, William
    Polidori, David
    Di Prospero, Nicolas
    [J]. DIABETES, 2017, 66 : A371 - A371
  • [6] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Usiskin, Keith
    Leiter, Lawrence A.
    Forst, Thomas
    Polidori, David
    Xie, John
    Sha, Sue
    [J]. DIABETES, 2014, 63 : A284 - A284
  • [7] Canagliflozin (CANA) Reduces Serum Uric Acid (SUA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Davies, Michael
    Trujillo, Angelina
    Vijapurkar, Ujjwala
    Damara-Ju, C. V.
    Meininger, Gary
    [J]. DIABETES, 2014, 63 : A283 - A284
  • [8] Urinary Tract Infection (UTI) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nicolle, Lindsay E.
    Capuano, George
    Fung, Albert
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A296 - A296
  • [9] Lower Blood Pressure (BP) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Weir, Matthew R.
    Januszewicz, Andrzej
    Gilbert, Richard
    Gonzalez, Fernando Lavalle
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A278 - A278
  • [10] Effects of canagliflozin on biomarkers of cardiovascular stress in older patients with type 2 diabetes
    Sattar, N.
    Januzzi, J. L.
    Butler, J.
    Jarolim, P.
    Vijapurkar, U.
    Merton, K. W.
    Ren, J.
    Canovatchel, W.
    Desai, M.
    Davies, M. J.
    [J]. DIABETOLOGIA, 2017, 60 : S424 - S424
12345